Department of Cardiology, Hospital Universitari de Sant Joan.
Institut d'Investigació Sanitària Pere Virgili (IISPV).
Clin Interv Aging. 2021 Apr 29;16:739-745. doi: 10.2147/CIA.S305619. eCollection 2021.
The European Heart Rhythm Association (EHRA) score is a proven and validated tool for assessing the symptoms of atrial fibrillation (AF). Little is known about the variables related to this score and how it changes after cardioversion.
We analyzed 744 patients undergoing elective cardioversion in whom AF-related symptoms were assessed at baseline and after 6 months of follow-up using the EHRA score. We assessed the association between the EHRA score and other clinical and echocardiographic variables at baseline and after 6 months of follow-up.
At 6 months of follow-up, we observed a reduction in the EHRA score in 50% and worsening in 2.8% of patients who remained in sinus rhythm (SR) compared with 34.6% and 11.3%, respectively, of patients with AF episodes (p<0.0001). Patients who maintained SR at 6 months were less symptomatic than those with AF (EHRA score 1.13 ± 0.35 vs 1.42 ± 0.59; p<0.0001). The independent predictors for reduction in the EHRA score after cardioversion were NYHA ≥II at baseline and maintenance of SR (p<0.0001).
The greatest improvement in AF-related symptoms was in patients who remained in SR at 6 months after cardioversion and in patients with worse NYHA functional class at baseline.
欧洲心脏病学会(EHRA)评分是评估心房颤动(AF)症状的经过验证和有效的工具。关于与该评分相关的变量以及电复律后评分如何变化的信息知之甚少。
我们分析了 744 例接受择期电复律的患者,在基线和 6 个月随访时使用 EHRA 评分评估 AF 相关症状。我们评估了 EHRA 评分与基线和 6 个月随访时其他临床和超声心动图变量之间的关系。
在 6 个月的随访中,与仍保持窦性心律(SR)的患者相比,AF 发作的患者中分别有 50%的患者 EHRA 评分降低,2.8%的患者恶化,而有 34.6%和 11.3%的患者(p<0.0001)。在 6 个月时保持 SR 的患者比有 AF 的患者症状更轻(EHRA 评分 1.13±0.35 与 1.42±0.59;p<0.0001)。电复律后 EHRA 评分降低的独立预测因素是基线 NYHA ≥II 级和维持 SR(p<0.0001)。
在电复律后 6 个月仍保持 SR 的患者和基线 NYHA 功能分级较差的患者中,AF 相关症状的改善最大。